HAYWARD, Calif., March 18, 2015 /PRNewswire/ -- Anthera
Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of
an underwritten public offering of 5,555,556 shares of its common
stock, offered at a price of $4.50
per share. The Company estimates that the gross proceeds from the
offering, before deducting underwriting discounts and commissions
and other estimated offering expenses payable by Anthera, will be
$25 million. The offering is expected
to close on or about March 23, 2015,
subject to customary closing conditions. In addition, Anthera has
granted the underwriter a 30-day option to purchase up to an
additional 833,333 shares of common stock to cover over-allotments,
if any. The Company intends to use the net proceeds from the
offering for clinical research and development and general
corporate purposes.
Piper Jaffray & Co. is acting
as sole underwriter in the offering. The Trout Group, LLC has acted
as advisor to the Company.
The securities described above are being offered by the Company
pursuant to a shelf registration statement previously filed with,
and declared effective by, the Securities and Exchange Commission
(the "SEC"). A final prospectus supplement and accompanying
prospectus relating to the offering will be filed with the SEC and
will be available on the SEC's website at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering, when available, may be
obtained from Piper Jaffray &
Co., Attention: Prospectus Department, at 800 Nicollet Mall,
J12S03, Minneapolis, MN 55402 or
by telephone at 800-747-3924 or by email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or jurisdiction.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused
on advancing the development and commercialization of innovative
medicines that benefit patients with unmet medical needs.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include statements about Anthera's
expectations with respect to its public offering, including
statements about the completion, timing and size of the offering,
the expected gross proceeds from the offering and Anthera's
anticipated use of proceeds from the offering. Such statements are
based on Anthera's expectations as of the date of this press
release and are subject to certain risks and uncertainties that
could cause actual results to differ materially, including but not
limited to the risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions
related to the proposed offering, as well as those set forth in
Anthera's public filings with the SEC, including Anthera's Annual
Report on Form 10-K for the year ended December 31, 2014. Anthera disclaims any intent
or obligation to update any forward-looking statements, whether
because of new information, future events or otherwise, except as
required by applicable law.
CONTACT: Dennis Lutz of Anthera
Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/anthera-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-300052354.html
SOURCE Anthera Pharmaceuticals, Inc.